Trends on epidemiological, virological, and clinical features among newly diagnosed HIV‐1 persons in Northwest Spain over the last 10 years. Issue 8 (16th March 2015)

• Record Type: Journal Article
• Authors: Pernas, B.; Mena, A.; Cañizares, A.; Grandal, M.; Castro‐Iglesias, A.; Pértega, S.; Pedreira, J.D.; Poveda, E.
• Is Part Of: Journal of medical virology. Volume 87:Issue 8(2015:Aug.)
• Page Start: 1319
• Page End: 1326
• Publication Date: 2015-03-16
• Subjects: Virology -- Periodicals; 616
• DOI: 10.1002/jmv.24185
• Languages: English
• ISSNs: 0146-6615

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="jmv24185-sec-0001" sec-type="section"> <p>To describe temporal trend and characteristics of newly HIV‐diagnosed patients in a medical care area in Northwest Spain over the last 10 years. All newly diagnosed patients for HIV‐infection from 2004 to 2013 at a reference medical care area in Northwest of Spain were identified. Epidemiological, virological, immunological, and clinical data, as well as HIV genotype and drug resistance information were recorded. A total of 565 newly HIV‐diagnosed patients were identified. The number of new cases increased in the last 5 years (66 cases/year). Overall, 53.1% had a median CD4 counts < 350 cells/µl and 33.6% had an AIDS defining criteria. Non‐B variants were found in 34.4% of patients being subtype F (25.8%) the most common non‐B subtype. The rate of transmitted drug resistance (TDR) over the study period was 3.7%, but a decreased to 2.6% was observed in the last 5 years. The most prevalent TDR mutations were: T215 revertants (1.5%), K219QENR (1.2%), for NRTIs; K103N (1.9%), for NNRTIs; L90M (0.3%), for PIs. Overall, 73.2% of patients started antiretroviral treatment and 9.9% of patients died during follow‐up. The number of newly HIV diagnosed patients increased since year 2009. There is a high prevalence of late diagnosis (53%) and 33% had an AIDS defining criteria. Interestingly, the most prevalent non‐B subtype in our population was F (25.8%). These findings support the need to facilitate the access for HIV testing to reduce the rate of late HIV diagnosis, improve the clinical outcome and prevent HIV transmission. <bold><italic>J. Med. Virol. 87:1319–1326, 2015</italic>.</bold> © 2015 Wiley Periodicals, Inc.</p> </sec> </abstract>